Promoting High Quality Care in Clinical Trials for Patients with Neuroendocrine Tumors (NETs) Abstract #1449

Introduction: The European Institute of Oncology is an ENETS Center of Excellence. Many patients (pts) are treated in clinical trials. The clinical research nurse (CRN) is a key figure in care delivery. Optimising staff resources means some trial activities are delivered by nursing staff with limited research experience. To provide high quality care & accurate trial results, all nursing staff caring for NET pts should have appropriate trial related support and training.
Aim(s): To involve nursing staff, develop knowledge, ensure pt safety and high quality research in NET studies.
Materials and methods: We used the Plan-Do-Check-Act (PDCA) quality improvement tool, to problem solve and implement potential solutions - a methodology applied in various healthcare settings.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Sara Gazzabin

To read results and conclusion, please login ...

Further abstracts you may be interested in

#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
#1310 Current Trials in Neuroendocrine Tumours: A Systematic Review
Introduction: Trials in neuroendocrine tumours (NETs) have increased markedly in number over the last 10 years. Researchers do not have ready access to a summary of open trials to identify research gaps.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Segelov E, Millican J, Singh S, ...
Keywords: trials, review
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial
Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD, PhD Manuela Albertelli
Keywords: SSA high dose